MISSION
Delivers safe, effective, and robust medical products that protect U.S. forces against validated CBRN threats. CBMS applies government and industry best practices to develop or acquire Food and Drug Administration (FDA)-approved products within rigorously managed cost, schedule, and performance constraints.

DESCRIPTION
The Joint Biological Agent Identification and Diagnostic System (JBAIDS) is a reusable, portable, modifiable biological agent identification and diagnostic system capable of rapid, reliable, and simultaneous identification of multiple biological agents and other pathogens of operational concern. The ruggedized and hardened system is configured to support deployed medical personnel with the ability to identify specific biological organisms from clinical and environmental sources and samples. The JBAIDS anthrax, tularemia, plague, H5N1, and Q-fever detection systems are FDA-cleared for diagnostic use. JBAIDS is operated throughout the combat zone by medical laboratory personnel.

SYSTEM INTERDEPENDENCIES
None

PROGRAM STATUS
• 1QFY10: FDA clearance for Avian Flu (H5N1) in vitro diagnostic (IVD) kit
• 3QFY11: FDA clearance for Q-Fever IVD Kit
• 4QFY11: Complete Navy fielding (31 systems)

PROJECTED ACTIVITIES
• FY12-14: Procurement of Next Generation Diagnostic System (NGDS)
Chemical Biological Medical Systems-Diagnostics

FOREIGN MILITARY SALES
None

CONTRACTORS
Idaho Technologies (Salt Lake City, UT)